MARKET

ZSANQ

ZSANQ

Zosano Pharma Corp
OTCPK

Real-time Quotes | Nasdaq Last Sale

0.260
-0.055
-17.46%
Closed 15:39 07/01 EDT
OPEN
0.320
PREV CLOSE
0.315
HIGH
0.320
LOW
0.260
VOLUME
10.66K
TURNOVER
2.98K
52 WEEK HIGH
37.28
52 WEEK LOW
0.260
MARKET CAP
1.27M
P/E (TTM)
-0.0179
1D
5D
1M
3M
1Y
5Y
16 Stocks Moving in Tuesday's Pre-Market Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares rose 38% to $1.27 in pre-market trading following a Form 4 filing showing the purchase of 2,044,676 shares by CEO Salvatore Palella at an average price of $0.99.
Benzinga · 06/07 10:09
52 Stocks Moving In Monday's Mid-Day Session
Gainers DiDi Global Inc. (NYSE: DIDI) jumped 51.4% to $2.80 after the Chinese government said the company can resume adding new users.
Benzinga · 06/06 16:11
69 Biggest Movers From Friday
Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/06 09:31
ADAP, SLDP and ZSAN among mid-day movers
Gainers: Turning Point Therapeutics (TPTX) +117%. Energy Focus (EFOI) +40%. Galecto (GLTO) +25%. Adaptimmune (ADAP) +22%. Amylyx Pharmaceuticals (AMLX) +22%. AudioEye (AEYE) +20%. Sprague Resources LP (SRLP) +20%. Global Cord
Seekingalpha · 06/03 16:42
40 Stocks Moving In Friday's Mid-Day Session
 Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares jumped 115.8% to $73.72 after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
Benzinga · 06/03 16:07
BRIEF-Zosano Pharma Corp- On June 2 Co Got Notice From Nasdaq Indicating That Co’S Securities Will Be Delisted From Nasdaq
reuters.com · 06/03 12:17
Why Zosano Pharma Shares Are Getting Hammered Today
Zosano Pharma Corp (NASDAQ: ZSAN) shares are trading lower by 44.35% at $0.98 after the company announced it filed a voluntary petition for relief under chapter 11.
Benzinga · 06/02 18:42
Mid-Afternoon Market Update: Dow Surges Over 200 Points; Immunic Shares Slide
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining more than 200 points on Thursday.
Benzinga · 06/02 18:30
More
No Data
Learn about the latest financial forecast of ZSANQ. Analyze the recent business situations of Zosano Pharma Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ZSANQ stock price target is 21.00 with a high estimate of 21.00 and a low estimate of 21.00.
High21.00
Average21.00
Low21.00
Current 0.2600
EPS
Actual
Estimate
-2.14-1.61-1.07-0.54
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 44
Institutional Holdings: 1.91M
% Owned: 38.98%
Shares Outstanding: 4.90M
TypeInstitutionsShares
Increased
10
903.75K
New
5
11.94K
Decreased
2
5.55K
Sold Out
8
9.94K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
President/Chief Executive Officer/Director
Steven Lo
Chief Financial Officer
Christine Matthews
Lead Director/Independent Director
Kenneth Greathouse
Director
Kathy McGee
Director
Elaine Yang
Independent Director
Linda Grais
No Data
No Data
About ZSANQ
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its ransdermal microneedle system (the System). The System is designed to facilitate drug absorption into the bloodstream. The Company’s lead product candidate is Qtrypta (M207). Qtrypta is a formulation of zolmitriptan delivered utilizing its System. Zolmitriptan is a serotonin receptor agonists known as triptans and is used as an acute treatment for migraine. Qtrypta is designed for absorption of zolmitriptan into the bloodstream without dependence on the gastrointestinal (GI) tract. Its same formulation, development name C213, is the treatment to provide relief for cluster headache.

Webull offers kinds of Zosano Pharma Corp stock information, including OTCPK:ZSANQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZSANQ stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZSANQ stock methods without spending real money on the virtual paper trading platform.